Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Facing revolt on healthcare bill, U.S. Senate Republicans delay vote

U.S. Senate Republican leaders postponed a vote on a healthcare overhaul after resistance from members of their own party, and President Donald Trump summoned Republican senators to the White House to urge them to break the impasse.

Read More »

FDA Grants Priority Review of Xarelto sNDA

FDA accepted for Priority Review an sNDA for Xarelto for a 10 mg once-daily dose for reducing the risk of VTE after at least six months of standard anticoagulant therapy.

Read More »

Coherus Axes 30 Percent of Employees

In light of a rejection from the U.S. FDA, Coherus Biosciences disclosed to the U.S. SEC that it plans to pink-slip 30 percent of its staff.

Read More »

Two Former Ariad Directors Charged With Insider Trading

The U.S. Securities and Exchange Commission filed insider trading charges against two former executives and the husband of a former staffer of Ariad Pharmaceuticals.

Read More »

BioPharm Executive: Let’s Get Rid of Clinical Trials

We’re living in volatile times. If I were to put a positive spin on that, I’d say that we’re living in times where a lot of accepted ways of doing things are being questioned. And those questions can be healthy. Take the FDA, for example. Pretty much every new president pays at least some lip service to the idea of speeding up drug approvals, cutting red tape, and helping the life sciences become more innovative. But President Trump apparently seriously considered appointing Jim O’Neill or Balaji Srinivasan as FDA Commissioner. Both O’Neill and Srinivasan are associates of Silicon Valley libertarian/iconoclast Peter Thiel, and have argued that drugs should be approved on the basis of safety alone, with the “market” deciding on whether they’re effective. (Healthcare is hardly a market in the normal sense of the term, hence the quotes.) O’Neill in particular would have done away with most clinical trials altogether.

Read More »

AstraZeneca cancer drug trial prompts investors to take options cover

Investors in drugmaker AstraZeneca have taken defensive positions in the options market ahead of eagerly awaited results of a major trial of a lung cancer treatment.

Read More »

Who Will Take Care Of Your Dissertation? provides its customers with

Definitely the conditions are extremely different, or therefore the preparation for each and every kind ought to vary. Such publications typically include trial tests to allow you to prepare. Of all abilities and techniques you should achieve the IELTS test, terminology is unquestionably among the most vital. Also, you’ll understand that all my model IELTS […]

Read More »

DePuy Synthes Announces Acquisition of Sentio to Enable Innovation in Minimally Invasive Spine Surgery

DePuy Synthes Products Inc., part of the Johnson & Johnson Medical Devices Companies, announced today that it has acquired Innovative Surgical Solutions LLC, doing business as Sentio LLC.

Read More »

Alder’s migraine drug data disappoints

Alder BioPharmaceuticals’ late-stage study data on its experimental treatment to prevent episodic migraine fell short of investors’ expectation.

Read More »

FDA Tackles Drug Competition

The U.S. FDA is taking two new, important steps to increase competition in the market for prescription drugs and facilitate entry of lower-cost alternatives.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

August 2019 Focus: AI, AR/VR, Top 200 Medicines, Lions Health Takeaways, and more!


Ad Right Bottom